Utility of inflammatory markers in the management of coronary artery disease

This publication has 81 references indexed in Scilit:

• Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day
  The American Journal of Cardiology, 2003
• Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
  Diabetes Care, 2002
• Acute-Phase Reactants and Coronary Heart Disease
  Seminars in Vascular Medicine, 2002
• Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6
  Published by Oxford University Press (OUP) ,2000
• Inhibition of proinflammatory cytokine production by pravastatin
  The Lancet, 1999
• Acute-Phase Proteins and Other Systemic Responses to Inflammation
  New England Journal of Medicine, 1999
• Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial)
  The American Journal of Cardiology, 1996
• Fibrinogen Is a Predictor of Mortality in Coronary Heart Disease Patients
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1996
• The pathogenesis of atherosclerosis: a perspective for the 1990s
  Nature, 1993
• Fibrinogen as a Risk Factor for Stroke and Myocardial Infarction
  New England Journal of Medicine, 1984